Inmune Bio, Inc. (INMB) stock
INMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.03+0.07 (+7.29%)
Close on Nov 18, 2026Market cap $28.59MP/E –Yield –
Inmune Bio revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Inmune Bio's revenue for the twelve months ending Dec 31, 2025 was $50.00K, up 257.1% year over year. For fiscal 2025 it was $50.00K, up 257.1% from the year before. The highest annual figure on record is $374.00K in fiscal 2022.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $50.00K | +257.1% |
| FY2024 | Dec 31, 2024 | $14.00K | -91.0% |
| FY2023 | Dec 31, 2023 | $155.00K | -58.6% |
| FY2022 | Dec 31, 2022 | $374.00K | +106.6% |
| FY2021 | Dec 31, 2021 | $181.00K | +1545.5% |
| FY2020 | Dec 31, 2020 | $11.00K | – |
| FY2018 | Dec 31, 2018 | $0 | – |
| FY2017 | Dec 31, 2017 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | – |
| Q3 FY2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $50.00K | +257.1% |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $14.00K | -63.2% |
| Q4 FY2023 | Dec 31, 2023 | $28.00K | -71.1% |
| Q3 FY2023 | Sep 30, 2023 | $43.00K | -56.1% |
| Q2 FY2023 | Jun 30, 2023 | $46.00K | +187.5% |
| Q1 FY2023 | Mar 31, 2023 | $38.00K | -76.7% |
| Q4 FY2022 | Dec 31, 2022 | $97.00K | -40.5% |
| Q3 FY2022 | Sep 30, 2022 | $98.00K | +600.0% |
| Q2 FY2022 | Jun 30, 2022 | $16.00K | – |
| Q1 FY2022 | Mar 31, 2022 | $163.00K | +3975.0% |
| Q4 FY2021 | Dec 31, 2021 | $163.00K | – |
| Q3 FY2021 | Sep 30, 2021 | $14.00K | – |
| Q2 FY2021 | Jun 30, 2021 | $0 | – |
| Q1 FY2021 | Mar 31, 2021 | $4.00K | – |
| Q2 FY2019 | Jun 30, 2019 | $0 | – |
| Q1 FY2019 | Mar 31, 2019 | $0 | – |
| Q2 FY2018 | Jun 30, 2018 | $0 | – |
| Q1 FY2018 | Mar 31, 2018 | $0 | – |
See a number that looks wrong?